Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Source filing unavailable
Q2 2022 · —
Revenue$2.51M$2.51Mno prior Q2 2021 on file Net Income-$2.08M-$2.08Mno prior Q2 2021 on file EPS, diluted—
Operating Income-$2,106,000— Margins · derivedGross margin37.0%
Operating margin
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
-84.1%